Literature DB >> 18342888

Blunted ACTH response to dexamethasone suppression-CRH stimulation in posttraumatic stress disorder.

Andreas Ströhle1, Michael Scheel, Sieglinde Modell, Florian Holsboer.   

Abstract

Previous studies have suggested that patients with posttraumatic stress disorder (PTSD) have an enhanced negative feedback sensitivity of the hypothalamic-pituitary-adrenal (HPA) system and a blunted ACTH response to corticotropin releasing hormone (CRH). The effects of two dexamethasone dosages (0.75 and 1.5 mg) on the ACTH and cortisol concentrations after CRH stimulation (100 microg) were studied in eight patients with PTSD and matched healthy control subjects. Compared to healthy subjects, patients with PTSD have a blunted ACTH response to CRH. Cortisol concentrations were only significantly influenced by dexamethasone dosage. Our results give further evidence for a central role of the pituitary in reflecting changes of the negative feedback sensitivity of the HPA system in patients with PTSD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342888     DOI: 10.1016/j.jpsychires.2008.01.015

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  18 in total

1.  Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis.

Authors:  Maya Lebow; Adi Neufeld-Cohen; Yael Kuperman; Michael Tsoory; Shosh Gil; Alon Chen
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

2.  The neuroendocrinology of childhood trauma in personality disorder.

Authors:  Royce J Lee; Jessica Hempel; Aaron Tenharmsel; Tianmin Liu; Aleksander A Mathé; Alan Klock
Journal:  Psychoneuroendocrinology       Date:  2011-06-08       Impact factor: 4.905

3.  Genetic load is associated with hypothalamic-pituitary-adrenal axis dysregulation in macaques.

Authors:  B Ferguson; J E Hunter; J Luty; S L Street; A Woodall; K A Grant
Journal:  Genes Brain Behav       Date:  2012-10-13       Impact factor: 3.449

4.  Decreased daytime illumination leads to anxiety-like behaviors and HPA axis dysregulation in the diurnal grass rat (Arvicanthis niloticus).

Authors:  Tomoko Ikeno; Sean P Deats; Joel Soler; Joseph S Lonstein; Lily Yan
Journal:  Behav Brain Res       Date:  2015-12-09       Impact factor: 3.332

5.  Interpersonal trauma exposure and startle reactivity to uncertain threat in individuals with alcohol use disorder.

Authors:  Stephanie M Gorka
Journal:  Drug Alcohol Depend       Date:  2019-11-06       Impact factor: 4.492

6.  Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD.

Authors:  Rachel Yehuda; Janine D Flory; Laura C Pratchett; Joseph Buxbaum; Marcus Ising; Florian Holsboer
Journal:  Psychopharmacology (Berl)       Date:  2010-08-13       Impact factor: 4.530

7.  Sleep and hypothalamic pituitary adrenal axis responses to metyrapone in posttraumatic stress disorder.

Authors:  Sabra S Inslicht; Madhu N Rao; Anne Richards; Aoife O'Donovan; Carolyn J Gibson; Tierney Baum; Thomas J Metzler; Thomas C Neylan
Journal:  Psychoneuroendocrinology       Date:  2017-12-07       Impact factor: 4.905

Review 8.  HPA Axis Interactions with Behavioral Systems.

Authors:  Amy E B Packard; Ann E Egan; Yvonne M Ulrich-Lai
Journal:  Compr Physiol       Date:  2016-09-15       Impact factor: 9.090

9.  Suppressed neuroendocrine stress response in depressed women on job-stress-related long-term sick leave: a stable marker potentially suggestive of preexisting vulnerability.

Authors:  Kristina Wahlberg; Per Hamid Ghatan; Sieglinde Modell; Ake Nygren; Martin Ingvar; Marie Asberg; Markus Heilig
Journal:  Biol Psychiatry       Date:  2008-12-05       Impact factor: 13.382

Review 10.  Animal models of post-traumatic stress disorder and recent neurobiological insights.

Authors:  Annie M Whitaker; Nicholas W Gilpin; Scott Edwards
Journal:  Behav Pharmacol       Date:  2014-09       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.